Breanna Qin

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Printify, a technology platform headquartered in Latvia that makes it possible for anyone, anywhere, to sell customized products with zero upfront investment, on its merger with Printful, a Latvia-based technology company that helps ecommerce sellers of all sizes use production-on-demand and other fulfillment solutions to turn their ideas into brands and products.

Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.

Cooley advised Reverence Capital Partners’ portfolio company Transact Campus, an innovative campus technology and payment solutions company, on a definitive agreement signed by Reverence Capital Partners to sell Transact to Roper Technologies for $1.6 billion.

Cooley advised Boldend, a top cyber automation company developing software solutions that enhance and scale cyber capabilities, on its acquisition by SIXGEN, a full-spectrum provider of cyber products, operations and solutions to the US national security and critical infrastructure sectors.